U.S. Hemostats Market Size, Share & Industry Analysis, By Product (Active Hemostats [Thrombin-based Hemostats, and Fibrin Sealants], Passive Hemostats [Plant-based, Animal-based, and Others], Combination Hemostats, and Others), By Application (Trauma, Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery, Neurosurgery, and Others), By End-user (Hospitals & ASCs, Tactical Combat Casualty Care Centers, and Others), and Country Forecast, 2025-2032

The U.S. hemostats market size was valued at USD 1.60 billion in 2024. The market is projected to grow from USD 1.69 billion in 2025 to USD 2.62 billion by 2032, exhibiting a CAGR of 6.5% during the forecast period.

A hemostat is a medical device or dressing utilized to manage bleeding from blood vessels within the body. It is utilized in surgical procedures and also for controlling emergency bleeding. In recent years, the market has witnessed a significant increase in the adoption of hemostat products among healthcare professionals.

The market growth is driven by the rising number of surgical procedures across the U.S. The increasing prevalence of chronic diseases requiring surgical interventions, coupled with the rising occurrence of trauma and accidents, which further require surgical procedures, are some of the major factors supplementing market growth.

• For instance, according to data provided by Injury Experts in January 2023, in the U.S., a total of 35,766 fatal car accidents occurred in 2020. Additionally, 1,593,390 crashes resulted in injuries.

Thus, such a high number of road accidents has increased the need for effective blood loss management products.

Furthermore, the market comprises some prominent players such as Baxter, Johnson & Johnson Services, Inc., Pfizer Inc., Integra LifeSciences Corporation, and BD. These entities capture a significant portion of the market. The growing focus of these market players on receiving regulatory approvals for the launch of hemostat products is driving market growth in the U.S.

MARKET DYNAMICS

MARKET DRIVERS

Increasing Surgical Procedures are Driving the Hemostats Market in the U.S.

Hemostatic agents are used to facilitate hemostasis, the process of coagulating blood to prevent excessive bleeding. The increase in surgical procedures in the U.S. directly impacts the hemostat market, as hemostatic products play an important role in managing bleeding during surgeries. With the increasing number of surgical procedures, there is an increasing demand for hemostat products, driving market growth.

As a result of the rising aging population and the rising incidence of chronic diseases, there has been a rise in the number of surgical operations, including orthopedic surgeries, cardiovascular interventions, and general surgeries. Consequently, the significant increase in operations resulted in a higher need for hemostatic products.

• For example, as per the data provided by the Mass General Brigham Incorporated in November 2024, more than 900,000 cardiac surgeries, comprising coronary bypass surgeries, are performed in the U.S. every year.

Therefore, increasing the usage of hemostat products in surgical procedures to control bleeding is boosting the U.S. hemostats market growth.

Rising Technological Advancements in Products to Propel Market Growth

As the demand for hemostatic agents is growing at a significant rate, the key players operating in the market are focusing on the development of innovative and technologically advanced products. There are several advantages associated with these innovative products, such as increased efficiency in achieving hemostasis, reduced risk of infections, and others. Owing to these advantages, key companies are focusing on the development and manufacturing of products with several improved features. Additionally, widening the application areas of these products can increase their demand in various surgical procedures.

• For instance, in January 2023, Grifols announced positive topline results from a phase 3b clinical trial conducted using its fibrin sealant for the treatment of surgical bleeding in pediatric patients.

MARKET RESTRAINTS

Risk of Adverse Reactions from Hemostatic Agents is Hindering Their Adoption in the U.S. Market

The U.S. hemostat products market, comprising products used to manage bleeding in surgical operations and trauma treatment, encounters considerable difficulties due to the risk of adverse reactions associated with various hemostatic agents. These adverse reactions may cause complications for patients and raise concerns for healthcare providers, ultimately impeding market expansion.

• For example, SURGICEL original absorbable hemostat provided by Johnson & Johnson Services, Inc., causes several adverse events, such as paralysis and nerve damage, when these products are used in proximity to foramina in bone, areas of bony confine, the spinal cord, optic nerve, and chiasm. Another adverse event is blindness when SURGICEL products are placed in the anterior cranial fossa.

Therefore, the risk of adverse reactions associated with hemostatic agents can significantly impact the U.S. market.

Clinical Limitations Associated with Product to Impede Market Growth Prospects

One of the additional factors restraining the market growth is the clinical limitations associated with the use of these products during surgical procedures in the country. Limitations on the usage of these products to control excessive bleeding, despite their demonstrated effectiveness, result in the limited adoption of these products by end-users. Additionally, the high cost of these products can further limit the market growth to a certain extent.

• For example, according to a study published by Elsevier in June 2021, the cost of hemostatic agents made with micro-fibrillar collagen was higher than that of other absorbable agents. Similarly, biologically active agents made with virus-inactivated human fibrinogen and human thrombin were priced higher than all absorbable agents.

MARKET OPPORTUNITIES

Research & Development of Hemostat Products to Provide Market Growth Opportunity

The increasing focus of market players on conducting preclinical and clinical trials in partnership with research institutions for the development and investigation of hemostatic products is expected to influence growth opportunities for the market.

• For instance, according to the information from ClinicalTrials.gov, a multicenter, randomized clinical research trial was launched by GATT Technologies BV in August 2022 in the U.S. and other areas. This study aimed to evaluate the clinical safety and effectiveness of GATT-Patch in comparison to TachoSil for managing hemostasis during elective open liver surgeries. This study was completed in May 2024, and the results indicated that GATT-Patch was used to treat minimal to moderate bleeding during liver surgery successfully and quickly achieve hemostasis with acceptable safety outcomes.

In the past few years, such clinical trials have grown rapidly, resulting in lucrative opportunities for both biopharmaceutical companies and technology manufacturers.

MARKET CHALLENGES

High Cost of Hemostat Products Considered a Significant Challenge for Market Expansion

The premium pricing of hemostat products, such as active hemostats, passive hemostats, and combination hemostats, results in them being unaffordable to a large portion of the low or middle-class population. This limits the accessibility for many patients and healthcare providers.

• For instance, the cost of Baxter Floseal Fast Prep Hemostatic Matrix 10 Ml ranges from USD 400.0 to USD 2,400.0. Also, as per the same source, the cost of Baxter’s Tachosil Absorbable Fibrin Sealant Patch 4.8cm x 4.8cm is USD 500.0.

Furthermore, the presence of other low-cost alternative options, such as surgical sutures and electrocautery, is one of the main factors challenging the market share of high-cost hemostat products and hindering market growth.

U.S HEMOSTATS MARKET TRENDS

Changing Preference for the Use of Hemostat Products in Minimally Invasive Surgeries Observed as a Notable Market Trend

The ongoing shift toward the use of hemostatic agents in minimally invasive surgery (MIS) is observed as a notable market trend fueled by technological developments, enhanced patient results, and the rising need for efficient surgical techniques.

Various market players are launching innovative hemostatic products to reduce bleeding in surgical operations.

• For example, in July 2023, Baxter introduced Perclot absorbable hemostatic powder in the U.S. market. This product is used as a supplementary hemostatic tool to manage bleeding during both open and laparoscopic surgeries, covering gynecologic, general, cardiovascular, and urological procedures.

The growing use of hemostat products in minimally invasive surgery (MIS) indicates a major trend in the surgical domain, emphasizing the ongoing need for effective blood loss management, enhanced patient recovery, and reduced postoperative complications.

Increasing Number of Hospitals and ASCs is Identified as Significant Market Trend

In the U.S., there is a technologically advanced healthcare infrastructure with an increasing number of hospitals and ASCs. This has increased the number of surgical procedures being performed at these facilities. This factor has also led to a high demand for a wide range of efficient products with strong features for managing bleeding complications during these surgical procedures.

Additionally, the number of ambulatory surgery centers (ASCs) in the U.S. is increasing at a steady pace.

• For instance, according to the data published by the Ambulatory Surgery Center Association and Ambulatory Surgery Foundation, in June 2023, the number of ASCs in the U.S. in 2022 was 6,109, and the number increased to more than 6,223 in 2023. This trend boosted the demand for hemostatic agents in the market.

Moreover, the increasing incidence of sports-related injuries and spinal ailments has also supplemented the growing need for hemostats.

Request a Free sample to learn more about this report.

IMPACT OF COVID-19

As a result of the COVID-19 pandemic, the market experienced a decrease in its revenue in 2020. Throughout the pandemic, numerous elective surgeries were delayed, resulting in a short-term decrease in the utilization of hemostats. In addition, market participants experienced a decrease in their revenues in 2020 as hospitals and surgical centers prioritized essential supplies, resulting in a short-term reduction in expenditures on specific hemostatic products.

• For instance, as per the 2020 annual report, Artivion, Inc. generated a revenue of USD 62.1 million in 2020 from its surgical sealants segment and witnessed a decline of -9.5% compared to USD 62.1 million generated in 2019.

In fiscal years 2021 and 2022, the market experienced consistent growth owing to increasing regulatory approvals and product launches. Moreover, in 2023 and 2024, the market experienced consistent growth driven by increased strategic initiatives, including partnerships and acquisitions, from market players and increased demand for hemostat products in minimally invasive surgeries.

Segmentation Analysis

By Product

Growing Regulatory Approvals and Product Launches Boosting Active Hemostat Segmental Growth

On the basis of product, the market is segmented into active hemostats, passive hemostats, combination hemostats, and others. The active hemostats segment is further divided into thrombin-based hemostats and fibrin sealants. Similarly, the passive hemostats segment is categorized into plant-based, animal-based, and others.

The active hemostats segment accounted for a dominant U.S. hemostats market share in 2024. The significant share of this segment is mainly due to increasing regulatory approvals and new product launches.

• For instance, in October 2024, Grifols, S.A. announced that its plasma-protein-based fibrin sealant, Vistaseal, for controlling surgical bleeding had received approval from the U.S. Food and Drug Administration (FDA) for pediatric patients.

The passive hemostats segment accounted for the second-largest market share in 2024, owing to the launch of new and innovative products, coupled with the easy availability of passive hemostats.

• For example, in August 2024, Cresilon Inc. announced that it had received the U.S. Food and Drug Administration (FDA) 510(k) clearance for TRAUMAGEL, a plant-based hemostatic gel technology for temporary external use for controlling moderate to severe bleeding.

The combination of hemostats and others segments is anticipated to grow throughout the forecast period. The technological advancements in hemostat products are the main factors driving the segment's growth.

By Application

Growing Number of General Surgery Augmented Segmental Growth

Based on application, this market is segmented into trauma, cardiovascular surgery, general surgery, plastic surgery, orthopedic surgery, neurosurgery, and others.

The general surgery segment held a dominant market share in 2024. An increasing number of patients admitted to public hospitals for general surgical procedures is fueling the segment’s growth.

• For instance, as per the data provided by the Australian Institute of Health and Welfare in November 2024, around 771,600 patients were admitted for surgery from public hospital elective surgery waiting lists in 2023, which was an increase of 4.9% compared to 2022.

The cardiovascular surgery segment held the second-largest market share in 2024 and is expected to grow at the highest CAGR during the forecast period. This is mainly due to the increasing number of cardiovascular surgeries across the U.S.

• For instance, as per the data provided by the Mass General Brigham Incorporated in November 2024, over 900,000 cardiac surgeries, including coronary bypass surgeries, are performed in the U.S. every year.


• Similarly, according to data published by RWJ Barnabas Health in October 2021, approximately 200,000 heart bypass surgeries are being performed every year in the U.S.

The plastic surgery segment is anticipated to grow at a stagnant CAGR throughout the forecast period owing to the increasing number of plastic surgeries performed in the U.S. and the increasing utilization of hemostat products in cosmetic surgeries.

• For example, according to the 2023 report of the American Society of Plastic Surgeons, published in September 2023, abdominoplasty is the most in-demand plastic surgery procedure in the U.S., with 170,110 procedures performed in 2023, experiencing an increase of 5.0% from the prior year.

The neurosurgery segment is expected to grow steadily throughout the forecast period, owing to the growing prevalence of neurological diseases requiring surgical procedures.

Moreover, the trauma segment is expected to grow moderately during the forecast period. This is mainly due to the increasing number of road accidents in the U.S.

• For instance, as per the data provided by Run Sensible Inc. in December 2024, the personal injury claims in the U.S. reached a total of approximately 400,000 cases in 2024. The primary sources of these claims were motor vehicle accidents, medical malpractice, workplace injuries, and many others.

On the other hand, the orthopedic surgery segment is projected to grow considerably from 2025-2032. This is mainly due to the increasing number of cases of joint-related diseases requiring orthopedic surgeries.

Furthermore, the others segment comprises urology, obstetrics and gynecology, and transplant. The others segment accounted for third-largest market share in 2024 and is expected to grow at a moderate CAGR during the forecast period. The increasing number of transplantation procedures in the U.S. is driving segmental growth.

• For instance, as per the data provided by IRODaT in December 2024, the total number of liver transplants from deceased donors was 29.44 per million population in the U.S. in 2023.

By End-user

Presence of Technologically Advanced Healthcare Facilities in the Hospitals & ASCs Assisted Segmental Growth

Based on end-user, the market is segmented into hospitals & ASCs, tactical combat casualty care centers, and others.

The hospitals and ASCs segment held a dominant market share in 2024 and is projected to grow at the highest CAGR during the forecast period. This was due to the availability of technologically advanced medical facilities in hospitals, along with an increasing patient shift toward receiving surgical treatment at ambulatory surgery centers. These are some of the important factors driving the segment’s growth.

• For instance, as per the data provided by the American Academy of Orthopedic Surgeons in November 2023, ambulatory surgery centers (ASCs) are playing an increasingly important role in the delivery of total joint arthroplasty care in the U.S. There were 42,228 procedural cases reported by ASCs in 2023, an 84.0% increase since 2022.

The tactical combat casualty care centers segment is estimated to grow moderately during the forecast period. The increasing need for combat activities due to rising instances of military conflict in the country is expected to boost the segment’s growth.

Others segment is expected to grow at a slower CAGR throughout the forecast period. Others segment include medical institutes and research centers where hemostat products are utilized to control bleeding conditions. The growing usage of hemostat products in research activities is driving segmental growth from 2025-2032.

COMPETITIVE LANDSCAPE

Key Market Players

Strong Focus of Key Players on Product Awareness is Responsible for Their Dominant Share in the Market

The market in the U.S. shows a consolidated structure, with well-established companies, such as Baxter, Johnson & Johnson Services, Inc., and Pfizer Inc., leading the market with a major share. Baxter dominated the market in 2024, owing to its strong focus on participating in conferences to create product awareness in the U.S. market.

• For instance, in November 2024, Baxter was present at the Stifel 2024 Healthcare Conference, held in New York, U.S. During the event, the company showcased its hemostat products to create product awareness in the market.

Other players, including Stryker, Integra LifeSciences Corporation, BD, Medtronic, and others, have increased their focus on strategic partnerships and new product launches to enhance their footprint in the U.S. market.

LIST OF KEY U.S. HEMOSTATS COMPANIES PROFILED

• Pfizer Inc. (U.S.)


• Johnson & Johnson Services, Inc. (U.S.)


• Integra LifeSciences (U.S.)


• Medtronic (Ireland)


• BD (U.S.)


• Stryker (U.S)


• Baxter (U.S.)


• Artivion, Inc. (U.S.)


• Aegis Lifesciences Private Limited (India)

KEY INDUSTRY DEVELOPMENTS

• October 2024: Johnson & Johnson Services, Inc. announced the availability of VISTASEAL in the U.S. market.


• January 2023: LifeGel Absorbable Surgical Hemostat, developed by Medcura, Inc., received the U.S. FDA’s Breakthrough Device Designation. This is the only product with this designation and can be used in surgical procedures where swelling cannot be tolerated.


• February 2022: Futura Surgicare Pvt. Ltd. introduced Hemostax (Oxidised Regenerated Cellulose). It is an absorbable hemostat that helps surgeons efficiently control bleeding.


• December 2021: BD acquired TissueMed, a company involved in the development of self-adhesive surgical sealant film. TissuePatch, the key product of TissueMed, claims to be useful in preventing leakages from surgical incisions.


• December 2020: Integra LifeSciences Corporation received premarket approval from the U.S. Food and Drug Administration (FDA) for its products, Helistat absorbable collagen hemostatic agent and Helitene absorbable collagen hemostatic agent.

REPORT COVERAGE

The report provides a detailed analysis of the market. It focuses on key areas, such as top products, applications, and end-users. In addition to the U.S. hemostats market trends, it highlights key industry developments, such as mergers, partnerships, & acquisitions, and the impact of COVID-19 on the market. The report also provides the competitive landscape of key companies at the U.S. level.

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation